Britain's medicine regulator approved Novo Nordisk's weight-loss pill on Thursday, making the UK the first market in Europe where patients can access the oral treatment and boosting the Danish drugmaker as it battles U.S. rival Eli Lilly.
The approval gives more than 10 million people with obesity in the UK an alternative to injections as drugmakers race to expand use of the medicines that have transformed weight-loss treatment and reshaped the global pharmaceutical industry.
